Capricor Inc.
Clinical trials sponsored by Capricor Inc., explained in plain language.
-
Hope for duchenne: new drug shows promise in Long-Term trial
Disease control OngoingThis study is for people with Duchenne muscular dystrophy who already took part in the HOPE-2 trial. It tests the long-term safety and effects of a drug called deramiocel, given every three months for about five years. The goal is to see if the drug can help maintain arm and hand…
Phase: PHASE2 • Sponsor: Capricor Inc. • Aim: Disease control
Last updated May 26, 2026 07:54 UTC
-
Cell therapy shows promise in slowing duchenne muscular dystrophy
Disease control OngoingThis study tests a cell therapy called deramiocel (CAP-1002) in 106 boys and young men with Duchenne muscular dystrophy (DMD), a genetic disease that weakens muscles over time. Participants receive either deramiocel or a placebo every 3 months for a year, then all can receive der…
Phase: PHASE3 • Sponsor: Capricor Inc. • Aim: Disease control
Last updated May 26, 2026 07:22 UTC